Annovis Bio (ANVS) Assets Average (2020 - 2026)
Annovis Bio (ANVS) posted Assets Average of $18.7 million for Q1 2026, down 2.47% sequentially from $19.1 million in Q4 2025, and down 8.21% YoY from $20.3 million in Q1 2025.
Annovis Bio (ANVS) Assets Average (2020 - 2026) Analysis & Trends
Annovis Bio has reported Assets Average for 7 years, with the latest figure at $18.7 million in Q1 2026.
- Quarterly Assets Average fell 8.21% year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (down 8.21% YoY) and the FY2025 annual result came in at $17.5 million, up 45.05% from the prior year.
- Assets Average declined to $18.7 million in Q1 2026 per ANVS's latest filing, from $19.1 million in the prior quarter.
- Over five years, Assets Average peaked at $45.0 million in Q1 2022 and troughed at $6.4 million in Q2 2024.
- A 5-year average of $22.6 million and a median of $19.3 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average surged 539.71% in 2022, then plunged 73.41% in 2024.
- Over 5 years, Assets Average stood at $36.6 million in 2022, then sank by 72.07% to $10.2 million in 2023, then soared by 38.45% to $14.1 million in 2024, then surged by 35.29% to $19.1 million in 2025, then dropped by 2.47% to $18.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $18.7 million, $19.1 million, and $19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | 19.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.66 Mn |
| Dec 31, 2025 | 19.14 Mn |
| Sep 30, 2025 | 19.32 Mn |
| Jun 30, 2025 | 24.10 Mn |
| Mar 31, 2025 | 20.33 Mn |
| Dec 31, 2024 | 14.14 Mn |
| Sep 30, 2024 | 9.70 Mn |
| Jun 30, 2024 | 6.43 Mn |
| Mar 31, 2024 | 9.01 Mn |
| Dec 31, 2023 | 10.22 Mn |
| Sep 30, 2023 | 16.52 Mn |
| Jun 30, 2023 | 24.18 Mn |
| Mar 31, 2023 | 30.78 Mn |
| Dec 31, 2022 | 36.57 Mn |
| Sep 30, 2022 | 38.54 Mn |
| Jun 30, 2022 | 42.03 Mn |
| Mar 31, 2022 | 45.05 Mn |
| Dec 31, 2021 | 46.83 Mn |
| Sep 30, 2021 | 48.57 Mn |
| Jun 30, 2021 | 27.73 Mn |